Impact of Preoperative MRI on Survival Outcomes in Patients with HER2-positive and Hormone Receptor–negative Breast Cancer

This is the authors' abstract. We don't add key points for this paper.

Background Little is known regarding the impact of preoperative breast MRI on the long-term outcomes of patients with breast cancer that is human epidermal growth factor receptor 2 (HER2) positive and hormone receptor negative. Purpose To evaluate the impact of preoperative breast MRI on recurrence-free survival (RFS) and overall survival (OS) in patients with HER2-positive and hormone receptor-negative breast cancer by using propensity score matching. Materials and Methods This retrospective study included women diagnosed with HER2-positive and hormone receptor-negative invasive ductal carcinoma between January 2007 and December 2016. Patients who underwent preoperative MRI (the MRI group) were matched with those who did not (the no-MRI group) using propensity score matching based on 19 clinical-pathologic covariates. RFS and OS were compared using Kaplan-Meier estimates, Cox proportional hazards models, and inverse probability weighting. Results Among 1094 women (median age, 52 years; age range, 24-91 years), 47.81% (523 of 1094) underwent preoperative MRI. The rates of total recurrence and death were 14.3% (75 of 523) and 7.07% (37 of 523) in the MRI group, respectively, compared with 16.5% (94 of 571) and 13.1% (75 of 571) in the no-MRI group. In the propensity score-matched set, preoperative MRI was not associated with total recurrence (hazard ratio [HR], 0.69; 95% CI: 0.47, 1.02; P = .06), local-regional recurrence (HR, 0.94; 95% CI: 0.52, 1.70; P = .84), contralateral breast recurrence (HR, 0.55; 95% CI: 0.24, 1.25; P = .15), or distant recurrence (HR, 0.56; 95% CI: 0.31, 1.03; P = .06). OS was not higher with preoperative MRI (HR, 0.63; 95% CI: 0.39, 1.00; P = .05). At multivariable analysis, preoperative MRI was not associated with improved RFS (HR, 0.89; 95% CI: 0.67, 1.19; P = .44) or OS (HR, 0.73; 95% CI: 0.48, 1.10; P = .14). Conclusion Preoperative MRI did not improve RFS or OS in patients with HER2-positive and hormone receptor-negative breast cancer.